- Report
- May 2024
- 391 Pages
Global
From €5337EUR$5,819USD£4,350GBP
- Report
- October 2024
- 187 Pages
Global
From €3365EUR$3,545USD£2,839GBP
€3739EUR$3,939USD£3,154GBP
- Report
- February 2025
- 193 Pages
Global
From €5316EUR$5,600USD£4,484GBP
- Report
- March 2025
- 250 Pages
Global
From €4262EUR$4,490USD£3,595GBP
- Report
- January 2025
- 123 Pages
Global
From €2847EUR$2,999USD£2,402GBP
- Report
- July 2024
- 100 Pages
Global
From €3560EUR$3,750USD£3,003GBP
- Report
- April 2024
- 180 Pages
Global
From €4272EUR$4,500USD£3,603GBP
- Report
- February 2025
- 219 Pages
Global
From €2373EUR$2,500USD£2,002GBP
- Report
- December 2024
- 150 Pages
Global
From €3750EUR$3,950USD£3,163GBP
- Report
- March 2024
- 118 Pages
Global
From €4272EUR$4,500USD£3,603GBP
- Report
- August 2024
- 72 Pages
United States
From €593EUR$625USD£500GBP
€1187EUR$1,250USD£1,001GBP
- Report
- January 2025
- 126 Pages
Europe
From €2847EUR$2,999USD£2,402GBP
- Report
- November 2024
- 319 Pages
Global
From €4556EUR$4,799USD£3,843GBP
- Report
- March 2025
- 175 Pages
Global
From €4262EUR$4,490USD£3,595GBP
- Report
- February 2025
- 200 Pages
Global
From €4262EUR$4,490USD£3,595GBP
- Report
- October 2024
- 202 Pages
Global
From €2326EUR$2,450USD£1,962GBP
- Report
- February 2025
- 185 Pages
Global
From €4272EUR$4,500USD£3,603GBP
- Report
- March 2025
- 2285 Pages
Global
From €1166EUR$1,271USD£950GBP
- Conference
- May 2025
- 2 Days
Global
€1594EUR$1,738USD£1,299GBP
€1839EUR$2,005USD£1,499GBP
- Report
- February 2025
- 227 Pages
Global
From €3845EUR$4,050USD£3,243GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more